A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

Elizabeth K. O'Donnell, Jacob P. Laubach, Andrew J. Yee, Tianqi Chen, Carol Ann Huff, Frank G. Basile, Philip M. Wade, Claudia E. Paba-Prada, Irene M. Ghobrial, Robert L. Schlossman, Jill N. Burke, Cynthia C. Harrington, Kathleen J. Lively, Hannah F. Lyons, Nikhil C. Munshi, Kenneth C. Anderson, Lorenzo Trippa, Paul G. Richardson, Noopur S. Raje

Research output: Contribution to journalArticle

Abstract

We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1·3 mg/m2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression-free survival (PFS) and overall survival (OS). Fifty-three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73 years (range 65-91). The ORR was 86% and 66% of patients achieved a very good partial response or better. Median PFS was 35·1 months (95% confidence interval 30·9-not reached) and median OS was not reached at a median follow-up of 30 months. Peripheral neuropathy was reported in 31 (62%) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well-tolerated and highly effective regimen, with robust PFS and OS, in the transplant-ineligible MM population.

Original languageEnglish (US)
JournalBritish Journal of Haematology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Multiple Myeloma
Dexamethasone
Transplants
Disease-Free Survival
Survival
Peripheral Nervous System Diseases
Population
Bortezomib
lenalidomide
Confidence Intervals
Safety
Therapeutics

Keywords

  • Multiple myeloma
  • Transplant-ineligible

ASJC Scopus subject areas

  • Hematology

Cite this

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. / O'Donnell, Elizabeth K.; Laubach, Jacob P.; Yee, Andrew J.; Chen, Tianqi; Huff, Carol Ann; Basile, Frank G.; Wade, Philip M.; Paba-Prada, Claudia E.; Ghobrial, Irene M.; Schlossman, Robert L.; Burke, Jill N.; Harrington, Cynthia C.; Lively, Kathleen J.; Lyons, Hannah F.; Munshi, Nikhil C.; Anderson, Kenneth C.; Trippa, Lorenzo; Richardson, Paul G.; Raje, Noopur S.

In: British Journal of Haematology, 01.01.2018.

Research output: Contribution to journalArticle

O'Donnell, EK, Laubach, JP, Yee, AJ, Chen, T, Huff, CA, Basile, FG, Wade, PM, Paba-Prada, CE, Ghobrial, IM, Schlossman, RL, Burke, JN, Harrington, CC, Lively, KJ, Lyons, HF, Munshi, NC, Anderson, KC, Trippa, L, Richardson, PG & Raje, NS 2018, 'A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma', British Journal of Haematology. https://doi.org/10.1111/bjh.15261
O'Donnell, Elizabeth K. ; Laubach, Jacob P. ; Yee, Andrew J. ; Chen, Tianqi ; Huff, Carol Ann ; Basile, Frank G. ; Wade, Philip M. ; Paba-Prada, Claudia E. ; Ghobrial, Irene M. ; Schlossman, Robert L. ; Burke, Jill N. ; Harrington, Cynthia C. ; Lively, Kathleen J. ; Lyons, Hannah F. ; Munshi, Nikhil C. ; Anderson, Kenneth C. ; Trippa, Lorenzo ; Richardson, Paul G. ; Raje, Noopur S. / A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. In: British Journal of Haematology. 2018.
@article{0e6e6a28cf5e46de8ca74d39bc888ad8,
title = "A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma",
abstract = "We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1·3 mg/m2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression-free survival (PFS) and overall survival (OS). Fifty-three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73 years (range 65-91). The ORR was 86{\%} and 66{\%} of patients achieved a very good partial response or better. Median PFS was 35·1 months (95{\%} confidence interval 30·9-not reached) and median OS was not reached at a median follow-up of 30 months. Peripheral neuropathy was reported in 31 (62{\%}) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well-tolerated and highly effective regimen, with robust PFS and OS, in the transplant-ineligible MM population.",
keywords = "Multiple myeloma, Transplant-ineligible",
author = "O'Donnell, {Elizabeth K.} and Laubach, {Jacob P.} and Yee, {Andrew J.} and Tianqi Chen and Huff, {Carol Ann} and Basile, {Frank G.} and Wade, {Philip M.} and Paba-Prada, {Claudia E.} and Ghobrial, {Irene M.} and Schlossman, {Robert L.} and Burke, {Jill N.} and Harrington, {Cynthia C.} and Lively, {Kathleen J.} and Lyons, {Hannah F.} and Munshi, {Nikhil C.} and Anderson, {Kenneth C.} and Lorenzo Trippa and Richardson, {Paul G.} and Raje, {Noopur S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/bjh.15261",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

AU - O'Donnell, Elizabeth K.

AU - Laubach, Jacob P.

AU - Yee, Andrew J.

AU - Chen, Tianqi

AU - Huff, Carol Ann

AU - Basile, Frank G.

AU - Wade, Philip M.

AU - Paba-Prada, Claudia E.

AU - Ghobrial, Irene M.

AU - Schlossman, Robert L.

AU - Burke, Jill N.

AU - Harrington, Cynthia C.

AU - Lively, Kathleen J.

AU - Lyons, Hannah F.

AU - Munshi, Nikhil C.

AU - Anderson, Kenneth C.

AU - Trippa, Lorenzo

AU - Richardson, Paul G.

AU - Raje, Noopur S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1·3 mg/m2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression-free survival (PFS) and overall survival (OS). Fifty-three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73 years (range 65-91). The ORR was 86% and 66% of patients achieved a very good partial response or better. Median PFS was 35·1 months (95% confidence interval 30·9-not reached) and median OS was not reached at a median follow-up of 30 months. Peripheral neuropathy was reported in 31 (62%) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well-tolerated and highly effective regimen, with robust PFS and OS, in the transplant-ineligible MM population.

AB - We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1·3 mg/m2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression-free survival (PFS) and overall survival (OS). Fifty-three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73 years (range 65-91). The ORR was 86% and 66% of patients achieved a very good partial response or better. Median PFS was 35·1 months (95% confidence interval 30·9-not reached) and median OS was not reached at a median follow-up of 30 months. Peripheral neuropathy was reported in 31 (62%) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well-tolerated and highly effective regimen, with robust PFS and OS, in the transplant-ineligible MM population.

KW - Multiple myeloma

KW - Transplant-ineligible

UR - http://www.scopus.com/inward/record.url?scp=85046539742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046539742&partnerID=8YFLogxK

U2 - 10.1111/bjh.15261

DO - 10.1111/bjh.15261

M3 - Article

C2 - 29740809

AN - SCOPUS:85046539742

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -